Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia
Conclusion: From the perspective of the analysis, the addition of dapagliflozin to standard treatment is a cost-effective option in patients with heart failure with reduced ejection fraction in Colombia.PMID:34702123 | DOI:10.1080/14737167.2022.1997595 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 27, 2021 Category: Health Management Authors: Yaneth Gil-Rojas Pieralessandro Lasalvia Ángel García Source Type: research

Economic evaluation of reproductive carrier screening for recessive genetic conditions: a systematic review
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct 26:1-10. doi: 10.1080/14737167.2022.1993063. Online ahead of print.ABSTRACTINTRODUCTION: Autosomal recessive (AR) and x-linked (XL) conditions are rare but collectively common which impact millions of people globally on morbidity, mortality and costs. Advanced medical technologies allow prospective parents to make informed reproductive decisions to avoid having affected children. Economic evaluations targeting on reproductive carrier screening (RCS) for AR and/or XL conditions have been conducted, but there has not been a systematic review in this area.AREAS COVERED: A systema...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Tianjiao Wang Mina Bahrampour Joshua Byrnes Paul Scuffham Edwin Kirk Martin Downes Source Type: research

Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis
CONCLUSION: Durvalumab consolidation therapy is likely to be cost-effective in China, which indicates that expensive immunotherapies can gain clinical benefits at a justifiable cost in developing countries as well.PMID:34643129 | DOI:10.1080/14737167.2022.1993062 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Xuan Chen Zhiguang Yang Guiyuan Xiang Lingna Gu Ziheng Qi Bin Wan Yun Lu Feng Chang Yumei Zhu Source Type: research

Economic Evaluation of Reproductive Carrier Screening for Recessive Genetic Conditions: A Systematic Review
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct 13. doi: 10.1080/14737167.2022.1993063. Online ahead of print.ABSTRACTINTRODUCTION: Autosomal recessive (AR) and x-linked (XL) conditions are rare but collectively common which impact millions of people globally on morbidity, mortality and costs. Advanced medical technologies allow prospective parents to make informed reproductive decisions to avoid having affected children. Economic evaluations targeting on reproductive carrier screening (RCS) for AR and/or XL conditions have been conducted, but there has not been a systematic review in this area.AREAS COVERED: A systematic s...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Tianjiao Wang Mina Bahrampour Joshua Byrnes Paul Scuffham Edwin Kirk Martin Downes Source Type: research

Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis
CONCLUSION: Durvalumab consolidation therapy is likely to be cost-effective in China, which indicates that expensive immunotherapies can gain clinical benefits at a justifiable cost in developing countries as well.PMID:34643129 | DOI:10.1080/14737167.2022.1993062 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Xuan Chen Zhiguang Yang Guiyuan Xiang Lingna Gu Ziheng Qi Bin Wan Yun Lu Feng Chang Yumei Zhu Source Type: research

Economic Evaluation of Reproductive Carrier Screening for Recessive Genetic Conditions: A Systematic Review
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct 13. doi: 10.1080/14737167.2022.1993063. Online ahead of print.ABSTRACTINTRODUCTION: Autosomal recessive (AR) and x-linked (XL) conditions are rare but collectively common which impact millions of people globally on morbidity, mortality and costs. Advanced medical technologies allow prospective parents to make informed reproductive decisions to avoid having affected children. Economic evaluations targeting on reproductive carrier screening (RCS) for AR and/or XL conditions have been conducted, but there has not been a systematic review in this area.AREAS COVERED: A systematic s...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Tianjiao Wang Mina Bahrampour Joshua Byrnes Paul Scuffham Edwin Kirk Martin Downes Source Type: research

Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis
CONCLUSION: Durvalumab consolidation therapy is likely to be cost-effective in China, which indicates that expensive immunotherapies can gain clinical benefits at a justifiable cost in developing countries as well.PMID:34643129 | DOI:10.1080/14737167.2022.1993062 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Xuan Chen Zhiguang Yang Guiyuan Xiang Lingna Gu Ziheng Qi Bin Wan Yun Lu Feng Chang Yumei Zhu Source Type: research

Economic Evaluation of Reproductive Carrier Screening for Recessive Genetic Conditions: A Systematic Review
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct 13. doi: 10.1080/14737167.2022.1993063. Online ahead of print.ABSTRACTINTRODUCTION: Autosomal recessive (AR) and x-linked (XL) conditions are rare but collectively common which impact millions of people globally on morbidity, mortality and costs. Advanced medical technologies allow prospective parents to make informed reproductive decisions to avoid having affected children. Economic evaluations targeting on reproductive carrier screening (RCS) for AR and/or XL conditions have been conducted, but there has not been a systematic review in this area.AREAS COVERED: A systematic s...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Tianjiao Wang Mina Bahrampour Joshua Byrnes Paul Scuffham Edwin Kirk Martin Downes Source Type: research

Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis
CONCLUSION: Durvalumab consolidation therapy is likely to be cost-effective in China, which indicates that expensive immunotherapies can gain clinical benefits at a justifiable cost in developing countries as well.PMID:34643129 | DOI:10.1080/14737167.2022.1993062 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Xuan Chen Zhiguang Yang Guiyuan Xiang Lingna Gu Ziheng Qi Bin Wan Yun Lu Feng Chang Yumei Zhu Source Type: research

Economic Evaluation of Reproductive Carrier Screening for Recessive Genetic Conditions: A Systematic Review
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct 13. doi: 10.1080/14737167.2022.1993063. Online ahead of print.ABSTRACTINTRODUCTION: Autosomal recessive (AR) and x-linked (XL) conditions are rare but collectively common which impact millions of people globally on morbidity, mortality and costs. Advanced medical technologies allow prospective parents to make informed reproductive decisions to avoid having affected children. Economic evaluations targeting on reproductive carrier screening (RCS) for AR and/or XL conditions have been conducted, but there has not been a systematic review in this area.AREAS COVERED: A systematic s...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Tianjiao Wang Mina Bahrampour Joshua Byrnes Paul Scuffham Edwin Kirk Martin Downes Source Type: research

Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis
CONCLUSION: Durvalumab consolidation therapy is likely to be cost-effective in China, which indicates that expensive immunotherapies can gain clinical benefits at a justifiable cost in developing countries as well.PMID:34643129 | DOI:10.1080/14737167.2022.1993062 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Xuan Chen Zhiguang Yang Guiyuan Xiang Lingna Gu Ziheng Qi Bin Wan Yun Lu Feng Chang Yumei Zhu Source Type: research

Economic Evaluation of Reproductive Carrier Screening for Recessive Genetic Conditions: A Systematic Review
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct 13. doi: 10.1080/14737167.2022.1993063. Online ahead of print.ABSTRACTINTRODUCTION: Autosomal recessive (AR) and x-linked (XL) conditions are rare but collectively common which impact millions of people globally on morbidity, mortality and costs. Advanced medical technologies allow prospective parents to make informed reproductive decisions to avoid having affected children. Economic evaluations targeting on reproductive carrier screening (RCS) for AR and/or XL conditions have been conducted, but there has not been a systematic review in this area.AREAS COVERED: A systematic s...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Tianjiao Wang Mina Bahrampour Joshua Byrnes Paul Scuffham Edwin Kirk Martin Downes Source Type: research

Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis
CONCLUSION: Durvalumab consolidation therapy is likely to be cost-effective in China, which indicates that expensive immunotherapies can gain clinical benefits at a justifiable cost in developing countries as well.PMID:34643129 | DOI:10.1080/14737167.2022.1993062 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Xuan Chen Zhiguang Yang Guiyuan Xiang Lingna Gu Ziheng Qi Bin Wan Yun Lu Feng Chang Yumei Zhu Source Type: research

Economic Evaluation of Reproductive Carrier Screening for Recessive Genetic Conditions: A Systematic Review
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct 13. doi: 10.1080/14737167.2022.1993063. Online ahead of print.ABSTRACTINTRODUCTION: Autosomal recessive (AR) and x-linked (XL) conditions are rare but collectively common which impact millions of people globally on morbidity, mortality and costs. Advanced medical technologies allow prospective parents to make informed reproductive decisions to avoid having affected children. Economic evaluations targeting on reproductive carrier screening (RCS) for AR and/or XL conditions have been conducted, but there has not been a systematic review in this area.AREAS COVERED: A systematic s...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Tianjiao Wang Mina Bahrampour Joshua Byrnes Paul Scuffham Edwin Kirk Martin Downes Source Type: research

Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis
CONCLUSION: Durvalumab consolidation therapy is likely to be cost-effective in China, which indicates that expensive immunotherapies can gain clinical benefits at a justifiable cost in developing countries as well.PMID:34643129 | DOI:10.1080/14737167.2022.1993062 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Xuan Chen Zhiguang Yang Guiyuan Xiang Lingna Gu Ziheng Qi Bin Wan Yun Lu Feng Chang Yumei Zhu Source Type: research

Economic Evaluation of Reproductive Carrier Screening for Recessive Genetic Conditions: A Systematic Review
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct 13. doi: 10.1080/14737167.2022.1993063. Online ahead of print.ABSTRACTINTRODUCTION: Autosomal recessive (AR) and x-linked (XL) conditions are rare but collectively common which impact millions of people globally on morbidity, mortality and costs. Advanced medical technologies allow prospective parents to make informed reproductive decisions to avoid having affected children. Economic evaluations targeting on reproductive carrier screening (RCS) for AR and/or XL conditions have been conducted, but there has not been a systematic review in this area.AREAS COVERED: A systematic s...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Tianjiao Wang Mina Bahrampour Joshua Byrnes Paul Scuffham Edwin Kirk Martin Downes Source Type: research

Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis
CONCLUSION: Durvalumab consolidation therapy is likely to be cost-effective in China, which indicates that expensive immunotherapies can gain clinical benefits at a justifiable cost in developing countries as well.PMID:34643129 | DOI:10.1080/14737167.2022.1993062 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Xuan Chen Zhiguang Yang Guiyuan Xiang Lingna Gu Ziheng Qi Bin Wan Yun Lu Feng Chang Yumei Zhu Source Type: research

Economic Evaluation of Reproductive Carrier Screening for Recessive Genetic Conditions: A Systematic Review
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct 13. doi: 10.1080/14737167.2022.1993063. Online ahead of print.ABSTRACTINTRODUCTION: Autosomal recessive (AR) and x-linked (XL) conditions are rare but collectively common which impact millions of people globally on morbidity, mortality and costs. Advanced medical technologies allow prospective parents to make informed reproductive decisions to avoid having affected children. Economic evaluations targeting on reproductive carrier screening (RCS) for AR and/or XL conditions have been conducted, but there has not been a systematic review in this area.AREAS COVERED: A systematic s...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Tianjiao Wang Mina Bahrampour Joshua Byrnes Paul Scuffham Edwin Kirk Martin Downes Source Type: research

Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis
CONCLUSION: Durvalumab consolidation therapy is likely to be cost-effective in China, which indicates that expensive immunotherapies can gain clinical benefits at a justifiable cost in developing countries as well.PMID:34643129 | DOI:10.1080/14737167.2022.1993062 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Xuan Chen Zhiguang Yang Guiyuan Xiang Lingna Gu Ziheng Qi Bin Wan Yun Lu Feng Chang Yumei Zhu Source Type: research

Economic Evaluation of Reproductive Carrier Screening for Recessive Genetic Conditions: A Systematic Review
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct 13. doi: 10.1080/14737167.2022.1993063. Online ahead of print.ABSTRACTINTRODUCTION: Autosomal recessive (AR) and x-linked (XL) conditions are rare but collectively common which impact millions of people globally on morbidity, mortality and costs. Advanced medical technologies allow prospective parents to make informed reproductive decisions to avoid having affected children. Economic evaluations targeting on reproductive carrier screening (RCS) for AR and/or XL conditions have been conducted, but there has not been a systematic review in this area.AREAS COVERED: A systematic s...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Tianjiao Wang Mina Bahrampour Joshua Byrnes Paul Scuffham Edwin Kirk Martin Downes Source Type: research

Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis
CONCLUSION: Durvalumab consolidation therapy is likely to be cost-effective in China, which indicates that expensive immunotherapies can gain clinical benefits at a justifiable cost in developing countries as well.PMID:34643129 | DOI:10.1080/14737167.2022.1993062 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 13, 2021 Category: Health Management Authors: Xuan Chen Zhiguang Yang Guiyuan Xiang Lingna Gu Ziheng Qi Bin Wan Yun Lu Feng Chang Yumei Zhu Source Type: research

Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Response to letter to the editor
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct 6:1-2. doi: 10.1080/14737167.2022.1986007. Online ahead of print.NO ABSTRACTPMID:34612137 | DOI:10.1080/14737167.2022.1986007 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 6, 2021 Category: Health Management Authors: Jorge A Gomez Diana Caceres Edisson Rodriguez Source Type: research

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer
CONCLUSIONS: Gefitinib was the most cost-effective treatment. In terms of QALYs gained, Osimertinib was more effective than all other TKIs. Nevertheless, with a Spanish threshold of €24,000/QALY, the reduction in the acquisition cost of osimertinib will have to be greater than 70%, to obtain a cost-effectiveness alternative.PMID:34602008 | DOI:10.1080/14737167.2022.1987220 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 4, 2021 Category: Health Management Authors: J Aguilar-Serra V Gimeno-Ballester A Pastor-Clerigues J Milara C Trigo-Vicente J Cortijo Source Type: research

A Novel Perspective on Pharmaceutical R & amp;D Costs; Opportunities for Reductions
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct 1. doi: 10.1080/14737167.2022.1987219. Online ahead of print.ABSTRACTINTRODUCTION: R&D costs as an element of medicines' pricing play a prominent role in the discussions regarding the affordability of medicine. This paper investigates details of R&D costs and potentials for reductions.AREAS COVERED: The manuscript focuses on the constitution of R&D costs in relation to medicines' pricing and its potential developments. The manuscript builds on a cost of opportunity approach to explore the results of potential changes in drug development and its possible economic, p...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 1, 2021 Category: Health Management Authors: Simon van der Schans Frans de Loos Cornelis Boersma Maarten J Postma Hans B üller Source Type: research

Cost of Illness in Multiple Sclerosis by Disease Characteristics - A Review of Reviews
In conclusion, although heterogeneity can make in-depth comparisons of costs across studies impossible, important patterns are broadly apparent.PMID:34582300 | DOI:10.1080/14737167.2022.1987218 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 28, 2021 Category: Health Management Authors: Dirk Schriefer Rocco Haase Nils Henning Ness Tjalf Ziemssen Source Type: research

Estimation of the economic burden of atrial fibrillation-related stroke in Greece
Conclusion: A F-related stroke imposes asignificant socioeconomic burden in Greece. Despite results relying on estimations, it seems that ensuring efficient reallocation of resources in appropriate prevention and early intervention strategies could decrease AF-related stroke's burden but also enhance healthcare systems' efficiency.Abbreviations: AF=atrial fibrillation.PMID:34569402 | DOI:10.1080/14737167.2021.1979961 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 27, 2021 Category: Health Management Authors: Konstantinos Vemmos Nadia Boubouchairopoulou Panagiotis Stafylas Elli Vitsou George Giannakoulas George Ntaios Haralampos Milionis George Hahalis Frangiskos Parthenakis Konstantinos Tsioufis Source Type: research

Letter to the editor regarding "Budget impact analysis of pneumococcal conjugate vaccines in Colombia"
Expert Rev Pharmacoecon Outcomes Res. 2021 Sep 25. doi: 10.1080/14737167.2022.1986006. Online ahead of print.NO ABSTRACTPMID:34569403 | DOI:10.1080/14737167.2022.1986006 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 27, 2021 Category: Health Management Authors: Juan M Reyes Jorge LaRotta Natalia Castano Mark A Fletcher Matthew Wasserman Johnna Perdrizet Rodrigo Sini de Almeida Source Type: research

In-hospital economic burden of anastomotic leakage after colorectal anastomosis surgery: a real-world cost analysis in Italy
Expert Rev Pharmacoecon Outcomes Res. 2021 Sep 25. doi: 10.1080/14737167.2022.1986389. Online ahead of print.ABSTRACTBACKGROUND: Anastomotic leakage (AL) is a severe complication of colorectal surgery. We aimed to quantify inpatient costs and key cost contributors associated with AL in a single Italian center.RESEARCH DESIGN AND METHODS: Electronic records for adults who had undergone colorectal surgery with anastomosis (January 2015 - December 2016), were retrospectively reviewed. Patients with AL were identified using clinical signs and/or imaging findings and/or intraoperative findings. Available data included patient, ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 27, 2021 Category: Health Management Authors: Gabriella Teresa Capolupo Thibaut Galvain Vito Parag ò Cyndy Tong Gianluca Mascian à Stefano Di Berardino Damiano Caputo Vincenzo La Vaccara Marco Caricato Source Type: research

Estimation of the economic burden of atrial fibrillation-related stroke in Greece
Conclusion: A F-related stroke imposes asignificant socioeconomic burden in Greece. Despite results relying on estimations, it seems that ensuring efficient reallocation of resources in appropriate prevention and early intervention strategies could decrease AF-related stroke's burden but also enhance healthcare systems' efficiency.Abbreviations: AF=atrial fibrillation.PMID:34569402 | DOI:10.1080/14737167.2021.1979961 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 27, 2021 Category: Health Management Authors: Konstantinos Vemmos Nadia Boubouchairopoulou Panagiotis Stafylas Elli Vitsou George Giannakoulas George Ntaios Haralampos Milionis George Hahalis Frangiskos Parthenakis Konstantinos Tsioufis Source Type: research

Letter to the editor regarding "Budget impact analysis of pneumococcal conjugate vaccines in Colombia"
Expert Rev Pharmacoecon Outcomes Res. 2021 Sep 25. doi: 10.1080/14737167.2022.1986006. Online ahead of print.NO ABSTRACTPMID:34569403 | DOI:10.1080/14737167.2022.1986006 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 27, 2021 Category: Health Management Authors: Juan M Reyes Jorge LaRotta Natalia Castano Mark A Fletcher Matthew Wasserman Johnna Perdrizet Rodrigo Sini de Almeida Source Type: research

In-hospital economic burden of anastomotic leakage after colorectal anastomosis surgery: a real-world cost analysis in Italy
Expert Rev Pharmacoecon Outcomes Res. 2021 Sep 25. doi: 10.1080/14737167.2022.1986389. Online ahead of print.ABSTRACTBACKGROUND: Anastomotic leakage (AL) is a severe complication of colorectal surgery. We aimed to quantify inpatient costs and key cost contributors associated with AL in a single Italian center.RESEARCH DESIGN AND METHODS: Electronic records for adults who had undergone colorectal surgery with anastomosis (January 2015 - December 2016), were retrospectively reviewed. Patients with AL were identified using clinical signs and/or imaging findings and/or intraoperative findings. Available data included patient, ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 27, 2021 Category: Health Management Authors: Gabriella Teresa Capolupo Thibaut Galvain Vito Parag ò Cyndy Tong Gianluca Mascian à Stefano Di Berardino Damiano Caputo Vincenzo La Vaccara Marco Caricato Source Type: research

Assessment of Quality of Life 8-Dimension (AQoL-8D): translation, validation, and application in two Dutch trials in patients with epilepsy and schizophrenia
CONCLUSION: Our results have shown that, among other things, AQoL-8D presents better ability to discriminate between known-groups and shows no ceiling effect. Based on our results, we would recommend the use of AQoL-8D in addition to EQ-5D-5L in trials assessing patient's quality of life in patients with epilepsy or schizophrenia.PMID:34553651 | DOI:10.1080/14737167.2021.1981861 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 23, 2021 Category: Health Management Authors: Hoi Yau Chan Ben F M Wijnen Micka ël Hiligsmann Filip Smit Loes A M Leenen Marian H J M Majoie Silvia M A A Evers Source Type: research

Assessment of Quality of Life 8-Dimension (AQoL-8D): translation, validation and application in two Dutch trials in patients with epilepsy and schizophrenia
CONCLUSION: Our results have shown that, amongst other things, AQoL-8D presents better ability to discriminate between known-groups and shows no ceiling effect. Based on our results, we would recommend use of AQoL-8D in addition to EQ-5D-5L in trials assessing patient's quality of life in patients with epilepsy or schizophrenia.PMID:34553651 | DOI:10.1080/14737167.2021.1981861 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 23, 2021 Category: Health Management Authors: Hoi Yau Chan Ben F M Wijnen Micka ël Hiligsmann Filip Smit Loes A M Leenen Marian H J M Majoie Silvia M A A Evers Source Type: research

Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population
CONCLUSION: COPD comorbidity imposes a significant economic burden on AECOPD.PMID:34530664 | DOI:10.1080/14737167.2021.1981291 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 17, 2021 Category: Health Management Authors: Chintal H Shah Eberechukwu Onukwugha Zafar Zafari Ester Villalonga-Olives Jeong-Eun Park Julia F Slejko Source Type: research

Economic Burden of Comorbidities Among COPD Patients Hospitalized for Acute Exacerbations: An Analysis of a Commercially Insured Population
CONCLUSION: : COPD comorbidity imposes a significant economic burden on AECOPD.PMID:34530664 | DOI:10.1080/14737167.2021.1981291 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 17, 2021 Category: Health Management Authors: Chintal H Shah Eberechukwu Onukwugha Zafar Zafari Ester Villalonga-Olives Jeong-Eun Park Julia F Slejko Source Type: research

Analysis of patients' access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece
CONCLUSIONS: The existing legislative measures at the national level of Bulgaria and Greece ensure adequate and timely access of patients with MS to treatment.PMID:34525887 | DOI:10.1080/14737167.2021.1981134 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 16, 2021 Category: Health Management Authors: Yoana Seitaridou Ivo Tsekov Maria Kamusheva Maria Dimitrova Guenka Petrova Source Type: research

Prevalence and direct costs of potentially inappropriate prescriptions in France: a population-based study
CONCLUSIONS: PIP prevalence is still high among French older adults, with substantial direct costs. Large scale interventions targeting most prevalent and/or costly PIPs are needed to reduce their clinical and economic impact.PMID:34525899 | DOI:10.1080/14737167.2021.1981863 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - September 16, 2021 Category: Health Management Authors: Barbara Roux Julien Bezin Camille Morival Pernelle Noize Marie-Laure Laroche Source Type: research